Table 7.

Comparison of clinical effectiveness between TNF-i with MTX (n = 40) and TNF-i without MTX (n = 9)

Variables	TNF-i without MTX (n = 9)	TNF-i with MTX (n = 40)	*P value
Cure of ulceration, n (%)	4/9 (44.4%)	21/40 (52.5%)	0.7252
Improvement of ulceration, n (%)	4/9 (44.4%)	23/40 (57.5%)	0.7126
Exacerbation of ulceration, n (%)	2/9 (22.2%)	10/40 (25%)	1.0000
Retention rate of TNF-i, n (%)	7/9 (77.8%)	33/40 (82.5%)	0.6631
Changes of DAIBD (month 0–1 year)	39.4 ± 35.7	44.5 ± 37.8	0.8460
Reduction in concomitant CS dose (month 0–1 year)	1.67 ± 3.53	6.13 ± 17.4	0.9191
CS less than 7.5 mg at year 1, n (%)	9/9 (100%)	36/40 (90.0%)	1.0000

Plus-minus values are means ± standard deviation. *P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease